Expert Outlook: Pacific Biosciences Through The Eyes Of 10 Analysts
Expert Outlook: Pacific Biosciences Through The Eyes Of 10 Analysts
专家展望：10位分析师眼中的太平洋生物科学
Pacific Biosciences (NASDAQ:PACB) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
太平洋生物科学公司（纳斯达克股票代码：PACB）在上个季度接受了10位分析师的分析，揭示了从看涨到看跌的一系列观点。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表总结了他们最近的评级，展示了过去30天内不断变化的情绪，并将其与前几个月进行了比较。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.4, a high estimate of $12.00, and a low estimate of $2.00. Experiencing a 50.56% decline, the current average is now lower than the previous average price target of $8.90.
分析师通过对12个月目标股价的评估提供了更深入的见解，显示平均目标价为4.4美元，最高估计为12.00美元，低估值为2.00美元。目前的平均价格下降了50.56％，现在低于之前的平均目标股价8.90美元。
Interpreting Analyst Ratings: A Closer Look
解读分析师评级：仔细观察
A comprehensive examination of how financial experts perceive Pacific Biosciences...
对金融专家如何看待太...
登录免费看全文
登录/注册